Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Share-based Compensation (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Share-based Compensation for 15 consecutive years, with $20.8 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 23.65% to $20.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $84.5 million through Dec 2025, up 37.73% year-over-year, with the annual reading at $84.5 million for FY2025, 37.73% up from the prior year.
  • Share-based Compensation hit $20.8 million in Q4 2025 for Corcept Therapeutics, down from $22.9 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $22.9 million in Q3 2025 to a low of $10.1 million in Q1 2021.
  • Historically, Share-based Compensation has averaged $14.0 million across 5 years, with a median of $12.4 million in 2023.
  • Biggest five-year swings in Share-based Compensation: dropped 4.17% in 2022 and later skyrocketed 64.77% in 2025.
  • Year by year, Share-based Compensation stood at $10.8 million in 2021, then dropped by 2.67% to $10.5 million in 2022, then rose by 24.18% to $13.1 million in 2023, then grew by 28.56% to $16.8 million in 2024, then increased by 23.65% to $20.8 million in 2025.
  • Business Quant data shows Share-based Compensation for CORT at $20.8 million in Q4 2025, $22.9 million in Q3 2025, and $19.0 million in Q2 2025.